Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962140 | 0.85 | SMN1; SMN2 (0.33) | RAB9ASMN1; SMN2 | |
| SCHEMBL22021469 | 0.82 | PKM (0.41) | NPC1RAB9ASMN1; SMN2MAPTHPGD | |
| SCHEMBL5884292 | 0.82 | SLC6A3 (0.35) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3600443 | 0.81 | SMN1; SMN2 (0.50) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL531672 | 0.81 | NPC1 (0.30) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31282934 | 0.81 | ALDH1A1 (0.32) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15349137 | 0.79 | MAPT (0.35) | NPC1RAB9ASMN1; SMN2MAPTHPGD | |
| SCHEMBL20681165 | 0.78 | HRH1 (0.30) | — | |
| SCHEMBL21963140 | 0.78 | SLC6A3 (0.40) | NPC1 | |
| SCHEMBL18758331 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| CN-113166065-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250002497-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2025-01-02 | — | — | US | disclosed |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| CN-108383858-B | Derivatives of imidazothiadiazoles and imidazopyrazines for the treatment of platelet aggregation | 百时美施贵宝公司 | 2024-09-20 | — | — | CN | disclosed |
| US-12084452-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240276957-A1 | METHODS OF TREATMENT WITH AMINOLEVULINIC ACID SYNTHASE 2 (ALAS2) MODULATORS | AGIOS PHARMACEUTICALS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-111094242-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150094297-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY | 2015-04-02 | — | — | US | disclosed |
| EP-2841437-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2015-03-04 | — | — | EP | disclosed |
| WO-2013163279-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20100047841-A1 | SYNTHESIS OF DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2010-02-25 | — | — | US | disclosed |
| US-20100047841-A1 | SYNTHESIS OF DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2010-02-25 | — | — | US | disclosed |
| WO-2008106080-A9 | SYNTHESIS OF DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2008106080-A2 | SYNTHESIS OF DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CA2 587/4885NPC1 178/4885RAB9A 1362/4885 |
| US-20150094297-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | CA2 1471/4885NPC1 4167/4885RAB9A 2789/4885 |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | TEKT1, TWF2, TEK | CA2 2254/4885NPC1 2990/4885RAB9A 2477/4885 |
| US-12084452-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, F2R, TMPRSS4 | CA2 1471/4885NPC1 4167/4885RAB9A 2789/4885 |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CA2 1245/4885NPC1 55/4885RAB9A 2131/4885 |
| US-20100047841-A1 | SYNTHESIS OF DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | XDH, XPA, TPX2 | CA2 4231/4885NPC1 3963/4885RAB9A 1629/4885 |
| US-20250002497-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | CA2 1459/4885NPC1 4076/4885RAB9A 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.